Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Novel Conjugated Unsaturated Ketones with Submicromolar Potencies Towards some Leukemic and Colon Cancer Cells

Author(s): Swagatika Das, H. Inci Gul, Umashankar Das*, Jan Balzarini, Stephen G. Dimmock and Jonathan R. Dimmock *

Volume 15, Issue 4, 2019

Page: [430 - 438] Pages: 9

DOI: 10.2174/1573406414666181015142633

Price: $65

Abstract

Background: Cancer continues to be the major health burden worldwide. There is an urgent need for the development of novel antineoplastic compounds to treat this devastating condition. Various alkylating anticancer drugs have been employed in the clinic for treating cancers. Unsaturated conjugated ketones are a group of alkylators which are of significant interest as potent antineoplastic agents.

Objective: The goal of this study is to discover unsaturated conjugated ketones which are novel potent cytotoxins displaying growth-inhibitory properties towards neoplasms and also to serve as cytotoxic warheads in drug development.

Methods: A variety of 3,5-bis (benzylidene)-4-piperidones 2a-n were synthesized and evaluated against a number of neoplastic cell lines. The short-term neurotoxicity of 2a-k, n was evaluated in mice by i.p. administration using doses level of 30, 100 and 300 mg/kg. Statistical correlations for determining structure-activity relationships were performed using an SPSS software.

Results: A number of compounds display cytotoxic potencies in the region of 10-7 to 10-8 M and some of the structural features contributing to the cytotoxicity were identified. Compounds 2a-d, 2h demonstrated substantially higher cytotoxic potencies compared to melphalan and 5- fluorouracil against a panel of leukemic and colon cancer cell lines. These lead cytotoxins comply with drug-likeness properties. In general, the antineoplastics 2 are well tolerated in mice using a short-term neurotoxicity screening.

Conclusion: In general, this group of compounds comprises excellent cytotoxic agents, which warrant their further development as cytotoxic warheads.

Keywords: Conjugated unsaturated ketones, cytotoxicity, colon cancer cells, structure-activity relationships, drug-likeness, apoptosis.

« Previous
Graphical Abstract

[1]
Chen, X.; Moore, M.J. Principles of Medical Pharmacology7th ed., Kalant, H.; Grant, D.M.; Mitchell, J. Eds.; Elsevier: Canada, 2007, p. 778.
[2]
Pati, H.N.; Das, U.; Sharma, R.K.; Dimmock, J.R. Cytotoxic thiol alkylators. Mini Rev. Med. Chem., 2007, 7, 131-139.
[3]
Dimmock, J.R.; Kandepu, N.M.; Hetherington, M.; Quail, J.W.; Pugazhenthi, U.; Sudom, A.M.; Chamankhah, M.; Rose, P.; Pass, E.; Allen, T.M.; Halleran, S.; Szydlowski, J.; Mutus, B.; Tannous, M.; Manavathu, E.K.; Myers, T.G.; De Clercq, E.; Balzarini, J. Cytotoxic activities of Mannich bases of chalcones and related compounds. J. Med. Chem., 1998, 41, 1014-1026.
[4]
Chen, G.; Waxman, D.J. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem. Pharmacol., 1994, 47, 1079-1087.
[5]
Tsutsui, K.; Komuro, C.; Ono, K.; Nishidia, T.; Shibamoto, Y.; Takahashi, M.; Abe, M. Chemosensitization by buthionine sulfoximine in vivo. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 1183-1186.
[6]
Dimmock, J.R.; Kumar, P.; Nazarali, A.J.; Motaganahalli, N.L.; Kowalchuk, T.P.; Beazely, M.A.; Quail, J.W.; Oloo, E.O.; Allen, T.M.; Szdlowski, J.; De Clercq, E. Balzarini, J. Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds. Eur. J. Med. Chem., 2000, 35, 967-977.
[7]
Karki, S.S.; Das, U.; Umemura, N.; Sakagami, H.; Iwamoto, S.; Kawase, M.; Balzarini, J.; De Clercq, E.; Dimmock, S.G.; Dimmock, J.R. 3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A novel class of potent tumor-selective cytotoxins. J. Med. Chem., 2016, 59, 763-769.
[8]
Dimmock, J.R.; Padmanilayam, M.P.; Puthucode, R.N.; Nazarali, A.J.; Motaganahalli, N.L.; Zello, G.A.; Quail, J.W.; Oloo, E.O.; Kraatz, H-B.; Prisciak, J.S.; Allen, T.M.; Santos, C.L.; Balzarini, J.; De Clercq, E.; Manavathu, E.K. A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. J. Med. Chem., 2001, 44, 586-593.
[9]
Topliss, J.G. A manual approach for applying the Hansch approach to drug design. J. Med. Chem., 1977, 20, 463-469.
[10]
Das, S.; Das, U.; Selvakumar, P.; Sharma, R.K.; Balzarini, J.; De Clercq, E.; Molnár, J.; Serly, J.; Baráth, Z.; Schatte, G.; Bandy, B.; Gorecki, D.K.; Dimmock, J.R. 3,5-Bis(benzylidene)-4-oxo-1-phosphonopiperidines and related diethyl esters: Potent cytotoxins with multi-drug-resistance reverting properties. ChemMedChem, 2009, 4, 1831-1840.
[11]
Baraldi, P.B.; Del, C.; Nunez, M.; Tabrizi, M.A.; De Clercq, E.; Balzarini, J.; Bermejo, J.; Estevez, F.; Romagnoli, R. Design, syntheses and biological evaluation of hybrid molecules containing α-methylene γ-butyrolactones and polyprrole minor groove binders. J. Med. Chem., 2004, 47, 2877-2886.
[12]
Grever, M.R.; Schepartz, S.A.; Chabner, B.A. The national cancer institute: Cancer drug discovery and development program. Semin. Oncol., 1992, 19, 622-638.
[13]
Porter, R.J.; Cereghino, J.J.; Gladding, G.D.; Hessie, B.J.; Kupferberg, H.J.; Scoville, B.; White, B.G. Antiepileptic drug development program. Cleveland. Clin. Q., 1984, 51, 293-305.
[14]
Hansch, C.; Leo, A.J. Substituent Constants for Correlation Analysis in Chemistry and Biology; John Wiley and Sons: New York, 1979, pp. 49-50.
[15]
Taft, R.W., Jr Separation of polar, steric and resonance effects in reactivity. In: Steric Effects in Organic Chemistry; Newman, M.S., Ed.; John Wiley and Sons: New York, 1956; p. 591.
[16]
Statistical Package for Social Sciences. SPSS for windows, Release 17.0; SPSS: Chicago, 2008.
[17]
Molinspiration Chemoinformatics. Available at: . www.molinspi-ration.com
[18]
Makarov, M.V.; Rybalkina, E.Y.; Roschenthaler, G-V.; Short, K.W.; Timofeeva, T.V.; Odinets, I.L. Design, cytotoxic and fluorescent properties of novel N-phosphorylalkyl substituted E, E, -3,5-bis(arylidene)piperid-4-ones. Eur. J. Med. Chem., 2009, 44, 2135-2144.
[19]
Richon, V.M.; Schulte, N.; Eastman, A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res., 1987, 47, 2056-2061.
[20]
Sheshkin, D. Handbook of Parametric and Nonparametric Statistical Procedures; Chapman and Hall: London, 2004, pp. 1093-1107.
[21]
Althaus, B. In: Textbook of Therapeutics, Drug and Disease Management; 7th ed., Herfindal, E.T.; Gorley, D.R., Eds.; Lippincott, Williams and Wilkins: London, 2000; p. 1724.
[22]
Remers, W.A. In Wilsan and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry10th ed.; Delgardo, J.N.; Remers, W.A., Eds.; Lippincott Raven Publishers: Philadelphia, 1998, p. 367.
[23]
Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery. Rev., 1997, 23, 3-25.
[24]
Veber, D.F.; Johnson, S.R.; Cheng, H-Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45, 2615-2623.
[25]
Kerns, E.H.; Di, L. Drug-like properties: Concepts, structure design and methods, Academic Press 2008.
[26]
Dunham, M.S.; Miya, T.A. A note on a simple apparatus for detecting neurological deficit in rats and mice. In: J. Amer. Pharm. Ass. Sci., Ed; , 1957; 46, pp. 208-209.
[27]
Das, S. Cytotoxic thiol alkylators containing the 1,5-diaryl-3-oxo- 1,4-pentadienyl pharmacophore (Ph.D. dissertation by SWAGATIKA DAS. Available at https://ecommons.usask.ca/handle/ 10388/ETD-2012-07-543

Rights & Permissions Print Cite
Article Metrics
40
4
1
1
© 2024 Bentham Science Publishers | Privacy Policy